Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredients in Maymetsi, are a biguanide and DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. They treat type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, provides regulatory documentation for global distribution, and manufactures the product under EU GMP guidelines for bulk or unit‑dose shipments to meet diverse market needs.

Maymetsi, a fixed‑dose combination of metformin and sitagliptin, is indicated for the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels and reduces HbA1c. - Monotherapy in metformin‑naïve patients: provides effective glycemic control as initial oral therapy. - Combination therapy with other antidiabetics: enhances glucose control when added to sulfonylureas, insulin or thiazolidinediones.

Maymetsi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Upper respiratory tract infection - Headache

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycemia, especially when combined with insulin or sulfonylureas - Pancreatitis

When prescribing Maymetsi, clinicians should consider several precautionary measures to ensure patient safety.

- Renal function: assess eGFR before initiation and monitor periodically. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor for signs of heart failure exacerbation. - Concomitant medications: review for drugs that may increase risk of hypoglycemia. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Maymetsi interacts with several medicines; understanding the interaction level guides safe co‑administration.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycemia. - Iodinated contrast agents: increase risk of metformin‑associated lactic acidosis. - Cimetidine: can raise sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics (especially loop diuretics): may affect renal clearance of metformin. - Rifampin: may reduce sitagliptin effectiveness. - ACE inhibitors or ARBs: monitor renal function when combined with metformin.